Roche in talks to buy Roivant Sciences drug for $7 billion, reveals The Wall Street Journal

Hacks at The Wall Street Journal landed a decent scoop overnight about Switzerland's Roche talks to buy a stomach drug from Roivant Sciences, the US-listed biotechnology group.

According to the WSJ report, Roche is looking to pay around $7 billion for drug, so no wonder Roivant's shares are up amost 16pc in the pre-market as the market capitlisation of the company is just under $9 billion...